News
CV, Cancer Risk Up With Tofacitinib for Rheumatoid Arthritis
Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met
Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met
No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept
JAK inhibitor baricitinib strongly recommended for the treatment of severe or critical COVID-19